|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/25/22 Ionis Pharmaceuticals Inc. 10-K 12/31/21 106:22M |
Document/Exhibit Description Pages Size
1: 10-K Ionis Pharmaceuticals, Inc. 10-K 12-31-2021 HTML 2.36M
2: EX-4.11 Instrument Defining the Rights of Security Holders HTML 47K
-- exhibit4-11
3: EX-10.19 Material Contract -- exhibit10-19 HTML 89K
4: EX-10.60 Material Contract -- exhibit10-60 HTML 65K
5: EX-10.83 Material Contract -- exhibit10-83 HTML 48K
6: EX-10.84 Material Contract -- exhibit10-84 HTML 830K
7: EX-21.1 Subsidiaries List -- exhibit21-1 HTML 30K
8: EX-23.1 Consent of Expert or Counsel -- exhibit23-1 HTML 30K
9: EX-31.1 Certification -- §302 - SOA'02 -- exhibit31-1 HTML 36K
10: EX-31.2 Certification -- §302 - SOA'02 -- exhibit31-2 HTML 36K
11: EX-32 Certification -- §906 - SOA'02 -- exhibit32-1 HTML 32K
17: R1 Document and Entity Information HTML 97K
18: R2 Consolidated Balance Sheets HTML 138K
19: R3 Consolidated Balance Sheets (Parenthetical) HTML 48K
20: R4 Consolidated Statements of Operations HTML 129K
21: R5 Consolidated Statements of Comprehensive Income HTML 62K
(Loss)
22: R6 Consolidated Statements of Stockholders' Equity HTML 110K
23: R7 Consolidated Statements of Cash Flows HTML 168K
24: R8 Consolidated Statements of Cash Flows HTML 41K
(Parenthetical)
25: R9 Organization and Significant Accounting Policies HTML 357K
26: R10 Investments HTML 156K
27: R11 Long-Term Obligations and Commitments HTML 109K
28: R12 Stockholders' Equity HTML 130K
29: R13 Income Taxes HTML 176K
30: R14 Collaborative Arrangements and Licensing HTML 163K
Agreements
31: R15 Akcea Merger HTML 49K
32: R16 Severance and Retention Costs related to our HTML 58K
Restructured Operations
33: R17 Employment Benefits HTML 35K
34: R18 Legal Proceedings HTML 35K
35: R19 Fourth Quarter Financial Data (Unaudited) HTML 82K
36: R20 Organization and Significant Accounting Policies HTML 415K
(Policies)
37: R21 Organization and Significant Accounting Policies HTML 267K
(Tables)
38: R22 Investments (Tables) HTML 158K
39: R23 Long-Term Obligations and Commitments (Tables) HTML 101K
40: R24 Stockholders' Equity (Tables) HTML 105K
41: R25 Income Taxes (Tables) HTML 175K
42: R26 Collaborative Arrangements and Licensing HTML 94K
Agreements (Tables)
43: R27 Akcea Merger (Tables) HTML 44K
44: R28 Severance and Retention Costs related to our HTML 57K
Restructured Operations (Tables)
45: R29 Fourth Quarter Financial Data (Unaudited) (Tables) HTML 82K
46: R30 Organization and Significant Accounting Policies, HTML 35K
Basis of Presentation (Details)
47: R31 Organization and Significant Accounting Policies, HTML 78K
Basic Net Income (Loss) per Share (Details)
48: R32 Organization and Significant Accounting Policies, HTML 105K
Diluted Net Income (Loss) per Share (Details)
49: R33 Organization and Significant Accounting Policies, HTML 113K
Revenue Recognition (Details)
50: R34 Organization and Significant Accounting Policies, HTML 42K
Contracts Receivable (Details)
51: R35 Organization and Significant Accounting Policies, HTML 32K
Deferred Revenue (Details)
52: R36 Organization and Significant Accounting Policies, HTML 59K
Research, Development and Patent Expenses
(Details)
53: R37 Organization and Significant Accounting Policies, HTML 40K
Accrued Liabilities (Details)
54: R38 Organization and Significant Accounting Policies, HTML 37K
Noncontrolling Interest in Akcea Therapeutics,
Inc. (Details)
55: R39 Organization and Significant Accounting Policies, HTML 45K
Cash, Cash Equivalents and Investments (Details)
56: R40 Organization and Significant Accounting Policies, HTML 44K
Inventory Valuation (Details)
57: R41 Organization and Significant Accounting Policies, HTML 67K
Property, Plant and Equipment (Details)
58: R42 Organization and Significant Accounting Policies, HTML 32K
Long-Lived Assets (Details)
59: R43 Organization and Significant Accounting Policies, HTML 65K
Stock-Based Compensation Expense (Details)
60: R44 Organization and Significant Accounting Policies, HTML 66K
Accumulated Other Comprehensive Loss (Details)
61: R45 Organization and Significant Accounting Policies, HTML 205K
Convertible Debt (Details)
62: R46 Organization and Significant Accounting Policies, HTML 36K
Call Spread (Details)
63: R47 Organization and Significant Accounting Policies, HTML 32K
Segment Information (Details)
64: R48 Organization and Significant Accounting Policies, HTML 127K
Fair Value Measurements (Details)
65: R49 Investments, Contract Maturity of HTML 50K
Available-for-Sale Securities (Details)
66: R50 Investments, Summary of Investments (Details) HTML 108K
67: R51 Investments, Investments Temporarily Impaired HTML 52K
(Details)
68: R52 Long-Term Obligations and Commitments, Long-Term HTML 56K
Obligations (Details)
69: R53 Long-Term Obligations and Commitments, Convertible HTML 101K
Debt and Call Spread (Details)
70: R54 Long-Term Obligations and Commitments, Research HTML 48K
and Development and Manufacturing Facilities
(Details)
71: R55 Long-Term Obligations and Commitments, Maturity HTML 58K
Schedules for Annual Debt and Other Obligations
(Details)
72: R56 Long-Term Obligations and Commitments, Operating HTML 86K
Leases (Details)
73: R57 Long-Term Obligations and Commitments, Future HTML 53K
Payments for Operating Lease Liabilities (Details)
74: R58 Stockholders' Equity, Preferred and Common Stock HTML 59K
(Details)
75: R59 Stockholders' Equity, Share Repurchase Program HTML 37K
(Details)
76: R60 Stockholders' Equity, Stock Plans (Details) HTML 134K
77: R61 Stockholders' Equity, Stock Option Activity HTML 86K
(Details)
78: R62 Stockholders' Equity, Restricted Stock Unit HTML 62K
Activity (Details)
79: R63 Stockholders' Equity, Stock-based Compensation HTML 47K
Expense (Details)
80: R64 Stockholders' Equity, Stock-based Valuation HTML 48K
Information (Details)
81: R65 Income Taxes, Income (Loss) Before Income Taxes HTML 40K
(Details)
82: R66 Income Taxes, Income Tax Expense (Benefit) HTML 55K
(Details)
83: R67 Income Taxes, Reconciliation of Statutory to HTML 116K
Effective Tax Rate (Details)
84: R68 Income Taxes, Deferred Tax Assets and Liabilities HTML 64K
(Details)
85: R69 Income Taxes, Tax Credit Carryforwards (Details) HTML 41K
86: R70 Income Taxes, Gross Unrecognized Tax Benefits HTML 44K
(Details)
87: R71 Collaborative Arrangements and Licensing HTML 206K
Agreements, Biogen (Details)
88: R72 Collaborative Arrangements and Licensing HTML 121K
Agreements, AstraZeneca (Details)
89: R73 Collaborative Arrangements and Licensing HTML 90K
Agreements, Bayer (Details)
90: R74 Collaborative Arrangements and Licensing HTML 69K
Agreements, GSK (Details)
91: R75 Collaborative Arrangements and Licensing HTML 99K
Agreements, Novartis (Details)
92: R76 Collaborative Arrangements and Licensing HTML 96K
Agreements, Roche (Details)
93: R77 Collaborative Arrangements and Licensing HTML 33K
Agreements, PTC Therapeutics (Details)
94: R78 Collaborative Arrangements and Licensing HTML 43K
Agreements, Bicycle License Agreement (Details)
95: R79 Collaborative Arrangements and Licensing HTML 52K
Agreements, Alnylam Pharmaceuticals, Inc.
(Details)
96: R80 Akcea Merger (Details) HTML 74K
97: R81 Severance and Retention Costs related to our HTML 49K
Restructured Operations, Restructured European
Operations (Details)
98: R82 Severance and Retention Costs related to our HTML 43K
Restructured Operations, Restructured North
American TEGSEDI Operations (Details)
99: R83 Employment Benefits (Details) HTML 37K
100: R84 Legal Proceedings (Details) HTML 32K
101: R85 Fourth Quarter Financial Data (Unaudited) HTML 156K
(Details)
104: XML IDEA XML File -- Filing Summary XML 194K
102: XML XBRL Instance -- form10k_htm XML 4.70M
103: EXCEL IDEA Workbook of Financial Reports XLSX 175K
13: EX-101.CAL XBRL Calculations -- ions-20211231_cal XML 335K
14: EX-101.DEF XBRL Definitions -- ions-20211231_def XML 1.79M
15: EX-101.LAB XBRL Labels -- ions-20211231_lab XML 3.59M
16: EX-101.PRE XBRL Presentations -- ions-20211231_pre XML 2.22M
12: EX-101.SCH XBRL Schema -- ions-20211231 XSD 308K
105: JSON XBRL Instance as JSON Data -- MetaLinks 624± 948K
106: ZIP XBRL Zipped Folder -- 0000874015-22-000079-xbrl Zip 1.32M
1. | I have reviewed this Annual Report on Form 10-K of Ionis Pharmaceuticals, Inc.; |
2. | Based
on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report; |
3. | Based on my knowledge, the consolidated financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, consolidated results of operations and consolidated cash flows of the
registrant as of, and for, the periods presented in this annual report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and |
d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions): |
a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Dated:
February 24, 2022 | |
/s/ BRETT P. MONIA | |
Brett P. Monia, Ph.D. | |
Chief Executive Officer |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 2/25/22 | |||
| Filed on: | 2/24/22 | 8-K | ||
| For Period end: | 12/31/21 | 5 | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/21/24 Ionis Pharmaceuticals Inc. 10-K 12/31/23 103:18M 2/22/23 Ionis Pharmaceuticals Inc. 10-K 12/31/22 110:25M |